Research Article
The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer
Table 1
Clinicopathological parameters for patients (
).
| Clinicopathological parameter | (%) |
| Age (years) | | ≤70 | 50 (42.4%) | >70 | 68 (57.6%) | Preoperative PSA level (ng/ml) | | <10 | 34 (28.8%) | 10-20 | 20 (16.9%) | >10 | 64 (54.3%) | Gleason score | | 2-6 | 33 (28.0%) | 7 | 30 (25.4%) | 8-10 | 55 (46.6%) | pT stage | | ≤T2 | 71 (60.1%) | >T2 | 47 (39.9%) | Metastasis | | Absent | 75 (63.6%) | Present | 43 (36.4%) | Hormone therapy | | No | 87 (73.7%) | Yes | 31 (26.3%) | Follow-up | | Alive | 61 (51.7%) | Dead | 25 (21.2%) | Loss | 32 (27.1%) | Surgical intervention | | Prostatectomy | 71 (60.2%) | TURP | 47 (39.8%) |
|
|
Abbreviations: pT stage: pathologic tumor stage; PSA: prostate-specific antigen; TURP: Transurethral Resection of the Prostate.
|